Direct Flow Medical said it raised nearly $31 million in a Series C funding round it hopes will eventually gross nearly $60 million.
The company is developing transcatheter replacements for the aortic and mitral heart valves. Direct Flow’s transcatheter aortic valve implant won CE Mark approval in the European Union in January 2013; enrollment is under way in a 1,000-patient U.S. pivotal trial of the device.
In February, the company debuted its TMVR entry, saying it hopes to begin 1st-in-human studies by the end of this year.
The company is developing transcatheter replacements for the aortic and mitral heart valves. Direct Flow’s transcatheter aortic valve implant won CE Mark approval in the European Union in January 2013; enrollment is under way in a 1,000-patient U.S. pivotal trial of the device.
In February, the company debuted its TMVR entry, saying it hopes to begin 1st-in-human studies by the end of this year.
